Related references
Note: Only part of the references are listed.Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Merryn Voysey et al.
LANCET (2021)
Evolution of antibody immunity to SARS-CoV-2
Christian Gaebler et al.
NATURE (2021)
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Merryn Voysey et al.
LANCET (2021)
Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19
Adam K. Wheatley et al.
NATURE COMMUNICATIONS (2021)
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness
Aziz Sheikh et al.
LANCET (2021)
Risk factors, symptom reporting, healthcare-seeking behaviour and adherence to public health guidance: protocol for Virus Watch, a prospective community cohort study
Andrew Hayward et al.
BMJ OPEN (2021)